Asset
REZPEGALDESLEUKIN
NEKTAR THERAPEUTICS COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06136741 | phase2 | active_not_recruiting | 2023-11-15 | 2025-05-06 | Nektar Therapeutics | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis |
| NCT06340360 | phase2 | completed | 2024-04-02 | 2025-11-26 | Nektar Therapeutics | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) |
| NCT07711418 | phase3 | recruiting | 2026-08-07 | 2028-06-01 | Nektar Therapeutics | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
| NCT07690371 | phase3 | recruiting | 2026-06-29 | 2028-05-01 | Nektar Therapeutics | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
| NCT05565729 | phase1 | completed | 2022-10-05 | 2023-02-23 | Nektar Therapeutics | A Phase I Study of LY3471851 in Healthy Participants |
FDA applications (0)
This company has no applications containing this asset.